Insider at

04

Insider transactions

05
0 buys (P) 2 sells (S) Net: $-31,339 + 13 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

13 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Sept. 10, 2026 LYEL S 500 $12.70 $6,350 20,423 Direct -2.39% Disposed -30.3% (price as of 2026-10-05)
June 10, 2026 LYEL S 1,977 $12.64 $24,989 20,923 Direct -8.63% Disposed -29.9% (price as of 2026-10-05)
Jan. 15, 2025 NKTX S 8,638 $2.20 $19,004 190,955 Direct -4.33% Disposed 12.0% (price as of 2026-10-05)
June 18, 2024 NKTX S 456 $5.60 $2,554 116,524 Direct -0.39% Disposed -56.0% (price as of 2026-10-05)
Jan. 16, 2024 NKTX S 3,552 $8.74 $31,044 114,980 Direct -3.00% Disposed -71.8% (price as of 2026-10-05)
Aug. 21, 2023 NKTX S 1,331 $1.83 $2,436 60,532 Direct -2.15% Disposed 34.7% (price as of 2026-10-05)
June 20, 2023 NKTX S 439 $4.85 $2,129 61,863 Direct -0.70% Disposed -49.2% (price as of 2026-10-05)
Jan. 17, 2023 NKTX S 175 $5.49 $961 60,302 Direct -0.29% Disposed -55.1% (price as of 2026-10-05)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Feb. 10, 2026 LYEL Option (right to buy) Common Stock (50,000) $23.71 Feb. 9, 2036 50,000 Acquired
June 9, 2025 LYEL Option (right to buy) Common Stock (43,750) $12.47 June 8, 2035 43,750 Acquired
Jan. 3, 2025 NKTX Stock Option (right to buy) Common Stock (117,500) $2.50 Jan. 2, 2035 117,500 Acquired
July 15, 2024 NKTX Stock Option (right to buy) Common Stock (30,000) $7.02 July 14, 2034 30,000 Acquired
Jan. 4, 2024 NKTX Stock Option (right to buy) Common Stock (112,500) $6.01 Jan. 3, 2034 112,500 Acquired
July 1, 2023 NKTX Stock Option (right to buy) Common Stock (208,000) $2.19 June 30, 2033 208,000 Acquired
Jan. 13, 2023 NKTX Stock Option (right to buy) Common Stock (75,000) $5.57 Jan. 12, 2033 75,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 11 holdings

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
Jan. 10, 2023 NKTX Common Stock 22,977 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (13,300) 13,300 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (4,300) 4,300 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (4,800) 4,800 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (4,680) 4,680 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (150) 150 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (3,310) 3,310 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (5,000) 5,000 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (7,000) 7,000 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (35,000) 35,000 Direct
Jan. 10, 2023 NKTX Stock Option (right to buy)→ Common Stock (30,000) 30,000 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

NKTX

M.D.(2)Chief Medical Officer, Head of Research and Development
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2024 $489,507 · $500,975 $723,122 $176,229 · $10,350 $1,900,182
2023 $459,800 · $208,875 $669,625 $161,850 · $9,900 $1,510,050

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.